XSPRAY — Xspray Pharma publ AB Share News
0.000.00%
Last trade - 00:00- SEK631.98m
- SEK659.11m
Sweden's Xspray Q1 loss narrows, upbeat on Dasynoc prospects
Brief: Xspray Pharma Q1 Pretax Loss SEK 35.4 Mln
Brief: Xspray Pharma To Receive About SEK 113 Million From Rights, Over-Allotment Issues
Brief: FDA Accepts Trade Name Nilopki For Xspray's Drug Candidate XS003
Brief: Xspray Increases Over-Allotment Issue
Brief: Xspray Pharma Resolves On Rights Issue Of SEK 83 Million
Brief: Xspray Pharma's Dasynoc Application Resubmission Accepted By FDA, Launch Targeted In H2
Brief: Xspray Pharma Re-Submits FDA Application For Dasynoc
Brief: Xspray Pharma Appoints Blake Leitch As CEO
Sweden's Xspray Q4 pretax loss narrows
Brief: Xspray Q4 Revenue SEK 0
Brief: Xspray Q3 Revenue SEK 0
Brief: Xspray Pharma Says FDA Accepts New Drug Application For Xs003 (Nilotinib)
Brief: Xspray: Rights Issue Oversubscribed, Over-Allotment Issue Increased And Fully Utilized
Brief: Xspray Pharma Submits XS003 To FDA; Review Expected Within 60 Days
Brief: Xspray Q2 Revenue SEK 0
Brief: Xspray Pharma Resolves On Rights Issue Of About SEK 130 Mln
Brief: Xspray Pharma Signs License Agreement With Handa Therapeutics
Brief: Xspray Pharma Completes PopPK Modeling For NDA Submission Of XS003